Protalix reports Q3 2026 results, reaffirms revenue guidance, RELEASE gout study enrolling
Protalix said its Phase 2 RELEASE study of PRX-115 for uncontrolled gout continues to enroll patients, with top-line results expected in the second half of 2027.
SEC filing